AcrobiosystemsLtd Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Yiding Chen

İcra Kurulu Başkanı

CN¥2.1m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	23.6%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Feb 12

Acrobiosystems Co.,Ltd. (SZSE:301080) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Acrobiosystems Co.,Ltd. ( SZSE:301080 ) shareholders have had their patience rewarded with a 26% share price jump in...

Analiz Makalesi • Nov 06

AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

A lackluster earnings announcement from Acrobiosystems Co.,Ltd. ( SZSE:301080 ) last week didn't sink the stock price...

Analiz Makalesi • Oct 01

Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%

Acrobiosystems Co.,Ltd. ( SZSE:301080 ) shares have had a really impressive month, gaining 27% after a shaky period...

Analiz Makalesi • Jul 15

Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price

There wouldn't be many who think Acrobiosystems Co.,Ltd.'s ( SZSE:301080 ) price-to-earnings (or "P/E") ratio of 30.8x...

Analiz Makalesi • May 02

AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

Shareholders didn't appear too concerned by Acrobiosystems Co.,Ltd.'s ( SZSE:301080 ) weak earnings. Our analysis...

CEO

Yiding Chen (49 yo)

no data

Görev süresi

CN¥2,056,500

Tazminat

Mr. Yiding Chen is General Manager & Chairman of the Board of Acrobiosystems Co.,Ltd.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yiding Chen	GM & Chairman of the Board	no data	CN¥2.06m	23.65% CN¥ 1.9b
Jingyun Miao	Deputy GM & Director	no data	CN¥1.27m	8.75% CN¥ 698.7m
Xu Huang	Deputy GM & Director	2.8yrs	CN¥1.01m	Veri yok
Feng Liu	Independent Director	6yrs	Veri yok	Veri yok
Yang Li	Non-Independent Director	2.8yrs	Veri yok	Veri yok
Zhang Yong	Independent Director	6yrs	Veri yok	Veri yok
Juanhong Xu	Independent Director	6yrs	Veri yok	Veri yok
Wenting Qu	Employee Supervisor	no data	Veri yok	Veri yok
Juanhong Xu	Independent Director	2.8yrs	Veri yok	Veri yok
Yangyang Yu	Non-Employee Supervisor	4.1yrs	Veri yok	Veri yok
Zhang Lin	Employee Supervisor	2.8yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 301080 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/30 13:09
Gün Sonu Hisse Fiyatı	2026/06/30 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Acrobiosystems Co.,Ltd. 11 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Pei Cheng	China Galaxy Securities Co., Ltd.
Shiyu Chen	China International Capital Corporation Limited
Zhu Chen	Citic Securities Co., Ltd.

AcrobiosystemsLtd Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Acrobiosystems Co.,Ltd., Annual General Meeting, May 12, 2026

Acrobiosystems Co.,Ltd., Annual General Meeting, May 14, 2025

Acrobiosystems Co.,Ltd., Annual General Meeting, May 14, 2024

Acrobiosystems Co.,Ltd. Approves Board Elections

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 16%

Acrobiosystems Co.,Ltd., Annual General Meeting, May 12, 2026

First quarter 2026 earnings released: EPS: CN¥0.28 (vs CN¥0.24 in 1Q 2025)

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Acrobiosystems Co.,Ltd. to Report Q1, 2026 Results on Apr 21, 2026

Investor sentiment deteriorates as stock falls 25%

Acrobiosystems Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 21, 2026

New major risk - Earnings quality

Third quarter 2025 earnings released: EPS: CN¥0.29 (vs CN¥0.16 in 3Q 2024)

Now 22% undervalued

Acrobiosystems Co.,Ltd. to Report Q3, 2025 Results on Oct 27, 2025

Now 20% undervalued

New major risk - Share price stability

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 14%

Second quarter 2025 earnings released: EPS: CN¥0.26 (vs CN¥0.15 in 2Q 2024)

Now 22% undervalued

Now 22% undervalued

Dividend of CN¥0.40 announced

Acrobiosystems Co.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

Price target increased by 13% to CN¥58.92

Acrobiosystems Co.,Ltd. Proposes Final Cash Dividend for the Year 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Acrobiosystems Co.,Ltd., Annual General Meeting, May 14, 2025

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 24%

Acrobiosystems Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025

Acrobiosystems Co.,Ltd. (SZSE:301080) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Investor sentiment improves as stock rises 15%

Acrobiosystems Co.,Ltd. Approves Profit Distribution Plan for Third Quarter 2024, Payable on 24 January 2025

Acrobiosystems Co.,Ltd. Proposes Third Quarter Dividend of 2024

Price target increased by 7.5% to CN¥49.08

Acrobiosystems Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 21, 2025

AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

Third quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.30 in 3Q 2023)

Investor sentiment deteriorates as stock falls 21%

Acrobiosystems Co.,Ltd. (SZSE:301080) announces an Equity Buyback for CNY 40 million worth of its shares.

Now 27% undervalued

Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%

New minor risk - Share price stability

Acrobiosystems Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 18%

Price target decreased by 17% to CN¥46.93

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.39 in 2Q 2023)

ACROBiosystems Launches GMP Brand Resilient Supply At ISSCR to Accelerate Cell and Gene Therapy Development

Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price

Acrobiosystems Co.,Ltd. Announces Implementation of Final Profit Distribution Plan (A Shares) for 2023, Payable on July 5, 2024

Acrobiosystems Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

Acrobiosystems Co.,Ltd., Annual General Meeting, May 14, 2024

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

Acrobiosystems Co.,Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Now 23% overvalued

Investor sentiment deteriorates as stock falls 16%

Acrobiosystems Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Acrobiosystems Launches Gmp Grade Dll4 Protein to Accelerate Stem Cell Manufacturing

Now 20% undervalued after recent price drop

New minor risk - Share price stability

Acrobiosystems Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

Acrobiosystems Co.,Ltd. Approves Board Elections

New major risk - Dividend sustainability

Investor sentiment deteriorates as stock falls 35%

Acrobiosystems Co.,Ltd. Approves the Cash Dividend for the Year 2022

Consensus revenue estimates decrease by 12%

Investor sentiment improved over the past week